Protara Therapeutics (TARA) Stock Price, News & Analysis

Company Overview

Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use.

The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease.

Protara was formed in 2019 through a merger involving ArTara Therapeutics. Its research and development activities focus on advancing these programs through clinical testing.

Key Stats

• Today's Range: $2.37 to $2.58
• 50-Day Range: $2.13 to $3.94
• 52-Week Range: $2.09 to $7.82
• Volume: 728,221 shs
• Average Volume: 926,978 shs
• Market Capitalization: $155.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.25
• Consensus Rating: Moderate Buy

Protara Therapeutics Stock Analysis - MarketRank™

Protara Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 352nd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Protara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Protara Therapeutics has a consensus price target of $26.25, representing about 937.5% upside from its current price of $2.53.

Amount of Analyst Coverage

Protara Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Protara Therapeutics are expected to decrease in the coming year, from ($1.37) to ($1.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protara Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protara Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Protara Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.93% of the float of Protara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protara Therapeutics has a short interest ratio ("days to cover") of 2.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Protara Therapeutics has recently decreased by 46.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protara Therapeutics does not currently pay a dividend.

Dividend Growth

Protara Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.90

News Sentiment

Protara Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Protara Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for TARA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Protara Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.60% of the stock of Protara Therapeutics is held by insiders.

Percentage Held by Institutions

38.13% of the stock of Protara Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 11/06/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TARA
• Previous Symbol: NASDAQ:PRTO
• CIK: 1359931
• Web: www.protaratx.com
• Phone: (646) 844-0337
• Fax: 781-487-6729
• Employees: 51
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Protara Therapeutics: $26.25
• High Price Target: $28.00
• Low Price Target: $24.00
• Potential Upside/Downside: +937.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -46.15%
• Return on Assets: -42.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.01
• Quick Ratio: 10.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.29 per share
• Price / Book: 1.10

Miscellaneous

• Outstanding Shares: 61,570,000
• Free Float: 56,891,000
• Market Cap: $155.77 million
• Optionable: Optionable
• Beta: 1.54